Search the Newsreel

Cellectar Biosciences Q2 2026 Earnings Preview

* Cellectar Biosciences (CLRB [https://seekingalpha.com/symbol/CLRB]) is scheduled to announce Q2 earnings results on Thursday, August 13th, before market open. * The consensus EPS Estimate is -$0.52 [https://seekingalpha.com/symbol/CLRB/earnings/estimates] (+84.7% Y/Y) and the consensus Revenue Estimate is $0M * Over the last 1 year, CLRB has …

EMBECTA CORP. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 17,

Bernstein Liebhard LLP reminds Embecta Corp. (NASDAQ: EMBC) investors that they have until August 17, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that Embecta made false and misleading statements about its business operations and financial stability between November 25, …

Galaxy Surfactants approves ₹22 final dividend at 40th AGM

Dimensional Fund Advisors LP Reduces Stake in Octave Specialty Group, Inc. $OSG

EMBC 6-DAY DEADLINE ALERT: Embecta Corp. Investors with

Hagens Berman is investigating Embecta Corp. (NASDAQ: EMBC) for alleged federal securities law violations after a class action lawsuit was filed. The lawsuit claims Embecta misrepresented the stability of its insulin pen needle business, leading to substantial investor losses. Investors who suffered losses between …

EMBC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Embecta Corp. to Contact the Firm Today!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Embecta Corp. (NASDAQ:EMBC) and its officers for alleged federal securities law violations. The firm encourages investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, to contact them, as …

Deadline Alert: Embecta Corp. (EMBC) Shareholders Who Lost

Glancy Prongay Wolke & Rotter LLP has issued a deadline alert for investors of Embecta Corp. (EMBC) who suffered losses. Shareholders who purchased securities between November 25, 2025, and May 4, 2026, are urged to contact the firm regarding a securities fraud lawsuit, with …

Embecta Corp. (EMBC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Embecta Corp. (EMBC), urging investors who suffered losses to come forward. The lawsuit alleges that Embecta made misleading statements between November 25, 2025, and May 4, 2026, regarding its …

EMBC Investor Announcement: Embecta Sued on behalf of Investors to Recover Losses after Insulin Pen Issues Lead to 57% Stock Drop

A class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and its executives for securities fraud. The lawsuit alleges that Embecta misled investors about the strength of its insulin pen needle product category, leading to a 57% stock drop after disappointing Q2 …

Kaplan Fox Encourages Investors of Embecta Corp. (NASDAQ: EMBC) to Contact the Firm Before Lead Plaintiff Deadline on August 17, 2026

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit follows a significant drop in Embecta's stock price after the company …

EMBC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Embecta Corp. Securities Lawsuit - Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for investors of Embecta Corp. (NASDAQ: EMBC) who purchased shares between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made misleading statements regarding its fiscal results, specifically its pen needle business, …

Embecta Corp. Notice of August 17, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline

Hagens Berman, a national shareholder rights law firm, is investigating Embecta Corp. (NASDAQ: EMBC) for alleged violations of federal securities laws after a class action lawsuit was filed. The lawsuit claims Embecta misrepresented the stability of its insulin pen needle business, leading to a …

EMBC INVESTOR ALERT: Embecta Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Hagens Berman is investigating Embecta Corp. (NASDAQ: EMBC) for alleged violations of federal securities laws, following a class action lawsuit claiming Embecta misrepresented the commercial stability of its insulin pen needle business. The lawsuit alleges the company's statements about its "stable" and "resilient" pen …

Stock Picks Today: Bharat Forge, Gland Pharma, Info Edge, Fractal Analytics, Vodafone And More On Brokerages' Radar

Empery Asset Management, LP Initiates Position in Cellectar Biosciences Inc (CLRB)

Empery Asset Management, LP has initiated a new position in Cellectar Biosciences Inc (CLRB) by purchasing 864,090 shares, representing 2.81% of its portfolio. This investment reflects Empery's focus on small-cap healthcare companies, despite CLRB's significant stock decline and poor financial health. Cellectar Biosciences is …

Cellectar Biosciences Sets Major Conference Schedule: Pediatric Cancer Data Featured

Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company, announced its participation in five major medical and industry conferences throughout September 2025. COO Jarrod Longcor will present on the company's Phospholipid Drug Conjugate™ (PDC) platform, including its lead asset iopofosine I 131, with notable …

Embecta adds to earnings rally with another 9% advance (EMBC:NASDAQ)

Embecta Corp. (EMBC) shares climbed another 9% on Monday, extending a rally initiated by the medical device company's strong quarterly earnings release. This surge brings the total rally to over 26% since the previous session, driven by better-than-expected non-GAAP EPS and revenue, and raised …

Embecta Q3 results beat analyst expectations

Embecta Corp. (Nasdaq: EMBC) reported Q3 results that surpassed analyst expectations, leading the company to raise its full-year adjusted earnings per share outlook. The medtech firm, specializing in insulin delivery, posted net income of $21.1 million on $271.7 million in revenue, with adjusted EPS …

Kaplan Fox & Kilsheimer LLP Alerts Embecta Corp. (NASDAQ: EMBC) Investors to a Securities Class Action Deadline on August 17, 2026

Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta's management knew or recklessly disregarded weaknesses in the …

Embecta Number of Employees 2026 | Employee Count & Headcount Data

Embecta Corp. (EMBC) had approximately 1,829 employees worldwide as of March 2026, representing a 14.7% decline from 2023. Despite the overall headcount reduction, Embecta is actively hiring, with 143 active job postings in 2026, a 43.4% increase from 2025. The company's workforce is primarily …

Cellectar Biosciences (CLRB) Sets Q3 2024 Earnings Call for Nov 18

Cellectar Biosciences (NASDAQ: CLRB) will report its third-quarter 2024 financial results and provide a corporate update on November 18, 2024, at 8:30 a.m. ET. Investors can access the conference call via a toll-free number or a webcast, with a replay available on the company's …

EMBC|Embecta Corp|Price:4.420|Chg%:+0.920

Embecta (EMBC) Stock Jumps On Profit Rebound Despite Lingering Debt Strain

Cellectar BioSciences (CLRB.US) will release its earnings report before the market opens on August 13.

Cellectar BioSciences (CLRB.US) is scheduled to release its earnings report on August 13. The report will be published before the market opens.

Overseas Shipholding Group Ord Shs Class A (OSG) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Overseas Shipholding Group Ord Shs Class A (OSG), detailing analyst ratings, price targets, and revenue/EPS estimates. Three analysts recommend a "Buy" for OSG, with a target price of $15.00, suggesting a significant upside. The company's next expected …

Overseas Shipholding Group Ord Shs Class A (OSG) Stock News Today

This page on TradingKey provides current stock information for Overseas Shipholding Group Ord Shs Class A (OSG). It displays the latest stock price, market capitalization, and indicates that more news and earnings reports are expected soon. The platform aims to offer comprehensive financial data …

Octave Specialty Group (NYSE:OSG) Posts Earnings Results, Misses Expectations By $0.03 EPS

EMBC Deadline: EMBC Investors with Losses in Excess of $100K Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit

The Rosen Law Firm is reminding investors who purchased Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026, of the August 17, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Embecta made false and …

Octave Specialty Group (OSG) Stock Sinks After Guidance Reset Cuts Earnings Outlook

Embecta forecasts $1.80-$1.90 FY2026 adjusted EPS while raising adjusted operating margin to 23.5%-24%

Earnings Call Insights: Embecta (EMBC) Q3 fiscal 2026 MANAGEMENT VIEW * "During the third quarter, Embecta generated total revenue of approximately $272 million" and "on a sequential basis, our third quarter financial performance improved significantly with revenue increasing approximately $50 million" (President, CEO & …

Embecta Corp. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:EMBC) 2026-08-07

Embecta Corp (EMBC) reported a strong sequential recovery in Q3 fiscal 2026, with revenue increasing by approximately $50 million and adjusted operating income rising by about $21 million compared to Q2. The company raised its fiscal 2026 adjusted operating margin guidance to 23.5%-24% and …

EQUITY ACTION ALERT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC)

Faruqi & Faruqi, LLP is reminding Embecta (EMBC) investors of the August 17, 2026 deadline to seek lead plaintiff status in a securities class action lawsuit. The lawsuit alleges that Embecta made misleading statements regarding its financial guidance, particularly its pen needle business, which …

Embecta Corp (EMBC) (Q3 2026) Earnings Call Highlights: Strong Sequential Recovery and Raised ...

Embecta Corp (EMBC) reported a strong sequential recovery in Q3 fiscal 2026, with revenue increasing by approximately $50 million and adjusted operating income rising by about $21 million compared to Q2. The company raised its fiscal 2026 adjusted operating margin guidance to 23.5%-24% and …

EMBECTA DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Embecta Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action – EMBC

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the “Class Period”), of the important August …

Embecta Corp. (Nasdaq: EMBC) Q3 2026 profit slides on revenue decline

Embecta Corp. (EMBC) reported a significant decline in Q3 2026 profits and revenue, with net income falling 53.6% to $21.1 million and revenue decreasing by 8.1% to $271.7 million, largely due to lower pricing and volumes. The company completed the $208.0 million acquisition of …

Embecta Corp. 2026: Revenue $271.7M, EPS $0.36— 10-Q Summary

Embecta Corp. reported its 2026 quarter results with revenue of $271.7 million and diluted EPS of $0.36, marking a significant decrease from the prior year. The revenue decline was attributed to lower volume and pricing pressure, despite the acquisition of Owen Mumford. The company …